

# Hepatitis A booster vaccination: is there a need?

Lancet, The

362, 1065-1071

DOI: [10.1016/s0140-6736\(03\)14418-2](https://doi.org/10.1016/s0140-6736(03)14418-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Vaccination options for last-minute travellers in need of travel-related prophylaxis against hepatitis A and B and typhoid fever: a practical guide. <i>Travel Medicine and Infectious Disease</i> , 2003, 1, 219-226.	1.5	23
2	Combined Hepatitis A and B Vaccines. <i>Drugs</i> , 2003, 63, 2625-2649.	4.9	31
4	Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. <i>Medical Journal of Australia</i> , 2004, 181, 482-485.	0.8	47
5	Viral hepatitis in the Arctic. <i>International Journal of Circumpolar Health</i> , 2004, 63, 41-48.	0.5	23
6	A novel process for production of hepatitis A virus in Vero cells grown on microcarriers in bioreactor. <i>World Journal of Gastroenterology</i> , 2004, 10, 2571.	1.4	14
7	Hepatitis vaccines. <i>British Medical Bulletin</i> , 2004, 70, 29-49.	2.7	10
8	Travelers' Knowledge, Attitudes and Practices on the Prevention of Infectious Diseases: Results from a Study at Johannesburg International Airport. <i>Journal of Travel Medicine</i> , 2004, 11, 16-22.	1.4	118
10	Hepatitis A. Current Treatment Options in <i>Gastroenterology</i> , 2004, 7, 443-450.	0.3	5
11	Hepatitis A vaccine: Indirect evidence of immune memory 12 years after the primary course. <i>Journal of Medical Virology</i> , 2004, 72, 194-196.	2.5	69
12	A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. <i>Expert Review of Vaccines</i> , 2004, 3, 249-267.	2.0	45
13	Prevention of Hepatitis A with the Hepatitis A Vaccine. <i>New England Journal of Medicine</i> , 2004, 350, 476-481.	13.9	111
14	Kinetics and clonality of immunological memory in humans. <i>Seminars in Immunology</i> , 2004, 16, 315-321.	2.7	19
15	Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults*. <i>Vaccine</i> , 2004, 23, 29-35.	1.7	26
16	Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. <i>Vaccine</i> , 2004, 23, 427-434.	1.7	57
22	Hepatitis A: A preventable threat. <i>Advances in Therapy</i> , 2005, 22, 578-586.	1.3	7
24	Hepatitis A. <i>Practice Nursing</i> , 2005, 16, 79-83.	0.1	0
25	Hepatitis A Immunization Strategies: Universal versus Targeted Approaches. <i>Clinical Pediatrics</i> , 2005, 44, 705-709.	0.4	9
26	Hepatitis A and B Booster Recommendations: Implications for Travelers. <i>Clinical Infectious Diseases</i> , 2005, 41, 1020-1026.	2.9	12

#	ARTICLE	IF	CITATIONS
27	Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 891-913.	0.9	11
28	Effect of Hepatitis A Vaccination Programs. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 246.	3.8	34
29	Hepatitis A vaccines: the growing case for universal immunisation of children. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 157-164.	0.9	15
30	Prevention of hepatitis A by Havrix®, a review. <i>Expert Review of Vaccines</i> , 2005, 4, 459-471.	2.0	39
32	Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. <i>Vaccine</i> , 2005, 23, 2424-2429.	1.7	42
33	Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. <i>Vaccine</i> , 2005, 23, 4110-4119.	1.7	45
34	Travel-related hepatitis B: risk factors and prevention using an accelerated vaccination schedule. <i>American Journal of Medicine</i> , 2005, 118, 63-68.	0.6	24
36	Prone Positioning in Children With ARDS. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 248.	3.8	12
37	What's next for the hepatitis A vaccine?. <i>Lancet, The</i> , 2006, 367, 546-548.	6.3	11
39	Prevention of viral hepatitis in HIV co-infection. <i>Journal of Hepatology</i> , 2006, 44, S104-S107.	1.8	22
40	Long-term immunity in young adults after a single dose of inactivated Hepatitis A vaccines. <i>Vaccine</i> , 2006, 24, 4328-4332.	1.7	29
41	Vaccination against hepatitis A and B: developments, deployment and delusions. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 456-459.	1.3	17
43	Immunogenicity and Safety of a Virosomal Hepatitis A Vaccine (Epaxal®) in the Elderly. <i>Journal of Travel Medicine</i> , 2006, 13, 78-83.	1.4	69
44	Risk of Exposure to Hepatitis B and Other Blood-Borne Viruses Among Australians Who Travel Abroad. <i>Journal of Travel Medicine</i> , 2006, 13, 345-350.	1.4	31
45	Excellent Booster Response 4 to 8 Years After a Single Primary Dose of an Inactivated Hepatitis A Vaccine. <i>Journal of Travel Medicine</i> , 2004, 11, 120-121.	1.4	41
46	Do We Need Hepatitis A Booster Vaccinations?. <i>Journal of Travel Medicine</i> , 2006, 11, 179-181.	1.4	11
47	Immunogenicity of Booster Vaccination with a Virosomal Hepatitis A Vaccine after Primary Immunization with an Aluminum-adsorbed Hepatitis A Vaccine. <i>Journal of Travel Medicine</i> , 2004, 11, 201-207.	1.4	17
51	Hepatitis A in the Era of Vaccination. <i>Epidemiologic Reviews</i> , 2006, 28, 101-111.	1.3	241

#	ARTICLE	IF	CITATIONS
52	The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2006, 43, 1499-1539.	2.9	234
53	Increasing hepatitis A IgG prevalence rate in men who have sex with men attending a sexual health clinic in London: implications for immunization policy. <i>International Journal of STD and AIDS</i> , 2007, 18, 707-710.	0.5	15
54	Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine. <i>Expert Review of Vaccines</i> , 2007, 6, 891-902.	2.0	21
55	Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United States. <i>Pediatrics</i> , 2007, 119, e12-e21.	1.0	68
56	Hepatitis A Vaccine Recommendations. <i>Pediatrics</i> , 2007, 120, 189-199.	1.0	101
58	Acute and Chronic Viral Hepatitis. , 0, , 369-446.		0
59	Marked decrease in the incidence and prevalence of hepatitis A in the Basque Country, Spain, 1986-2004. <i>Epidemiology and Infection</i> , 2007, 135, 402-408.	1.0	11
60	Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: Results from 8-year follow-up. <i>Vaccine</i> , 2007, 25, 446-449.	1.7	41
61	Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. <i>Vaccine</i> , 2007, 25, 927-931.	1.7	50
62	Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults. <i>Vaccine</i> , 2007, 25, 1503-1508.	1.7	22
63	Prevalence of hepatitis A virus risk factors in a very low endemic country, Switzerland. <i>Vaccine</i> , 2007, 25, 8718-8725.	1.7	11
65	A review of the long-term protection after hepatitis A and B vaccination. <i>Travel Medicine and Infectious Disease</i> , 2007, 5, 79-84.	1.5	111
66	Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix <sup>®</sup> ) in adults. <i>Travel Medicine and Infectious Disease</i> , 2007, 5, 171-175.	1.5	28
67	Immunisation of the travelling child. <i>Travel Medicine and Infectious Disease</i> , 2007, 5, 349-364.	1.5	7
68	Epidemiology of Travel-Associated and Autochthonous Hepatitis A in Austrian Children, 1998 to 2005. <i>Journal of Travel Medicine</i> , 2007, 14, 248-253.	1.4	9
70	The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. <i>Journal of Gastroenterology</i> , 2007, 42, 152-160.	2.3	45
72	Vaccine-preventable Diseases in Long-term Expatriates. <i>Journal of Travel Medicine</i> , 2008, 12, S47-S57.	1.4	7
73	Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. <i>Journal of Viral Hepatitis</i> , 2008, 15, 1-15.	1.0	92

#	ARTICLE	IF	CITATIONS
74	The need for an evidence-based decision-making process with regard to control of hepatitis A. <i>Journal of Viral Hepatitis</i> , 2008, 15, 16-21.	1.0	13
75	Recent advances with a virosomal hepatitis A vaccine. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1177-1185.	1.4	23
76	Epaxal <sup>®</sup> : a virosomal vaccine to prevent hepatitis A infection. <i>Expert Review of Vaccines</i> , 2008, 7, 1141-1150.	2.0	196
77	Hepatitis A: Disease Burden and Current Childhood Vaccination Strategies in the United States. <i>Journal of Pediatric Health Care</i> , 2008, 22, 3-11.	0.6	32
78	Hepatitis A vaccination effectiveness during an outbreak in the Ukraine. <i>Vaccine</i> , 2008, 26, 3135-3137.	1.7	3
79	Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. <i>Vaccine</i> , 2008, 26, 1759-1763.	1.7	20
80	Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction. <i>Vaccine</i> , 2008, 26, 1737-1741.	1.7	47
81	A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. <i>Vaccine</i> , 2008, 26, 4608-4616.	1.7	35
82	Hepatitis A vaccines. <i>Expert Review of Vaccines</i> , 2008, 7, 535-545.	2.0	55
83	Immunization of Healthy Adults. , 2008, , 85-120.		2
84	Persistence of Antibody to Hepatitis A Virus 10 Years after Vaccination among Children and Adults. <i>Journal of Infectious Diseases</i> , 2008, 198, 1776-1782.	1.9	61
85	Immunization issues in pediatric travelers. <i>Expert Review of Vaccines</i> , 2008, 7, 651-661.	2.0	6
86	Recent Epidemiological Status and Vaccination of Hepatitis A in Korea. <i>Journal of the Korean Medical Association</i> , 2008, 51, 110.	0.1	34
87	Seroepidemiology of Hepatitis A among Healthcare Workers and Their Response to Vaccination Recommendation at a Korean Hospital. <i>Infection and Chemotherapy</i> , 2009, 41, 272.	1.0	3
88	Hepatitis A Vaccination Rates and Related Factors in a 2005 Population-based Study in Nonsan, Korea. <i>Epidemiology and Health</i> , 2009, 31, e2009003.	0.8	6
89	Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses†. <i>Gynecologic Oncology</i> , 2009, 115, S1-S6.	0.6	131
91	Hepatitis A and B immunization for individuals with inherited bleeding disorders. <i>Haemophilia</i> , 2009, 15, 437-447.	1.0	12
92	Correlation between humoral and cellular immune responses and the expression of the hepatitis A receptor HAVcr-1 on T cells after hepatitis A re-vaccination in high and low-responder vaccinees. <i>Vaccine</i> , 2009, 27, 197-204.	1.7	25

#	ARTICLE	IF	CITATIONS
93	Comparison of the immunogenicity and safety of <i>Cervarix</i> and <i>Gardasil</i> human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. <i>Hum Vaccin</i> , 2009, 5, 705-719.	2.4	336
96	An outbreak of hepatitis A in Roma populations living in three prefectures in Greece. <i>Epidemiology and Infection</i> , 2010, 138, 1025-1031.	1.0	15
97	ADOLESCENT WITH NEUROPSYCHIATRIC SYMPTOMS ASSOCIATED WITH NOVEL INFLUENZA A (H1N1) VIRUS INFECTION. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 570-571.	1.1	16
98	HERPES ZOSTER IN HEALTHY INFANTS AND TODDLERS AFTER PERINATAL EXPOSURE TO VARICELLA-ZOSTER VIRUS. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 574-576.	1.1	21
99	Séroprévalence de l'hépatite virale A dans les ictères fébriles chez les enfants de la région de Marrakech, Maroc. <i>Journal De Pédiatrie Et De Puericulture</i> , 2010, 23, 76-81.	0.0	2
100	Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. <i>Journal of Medical Virology</i> , 2010, 82, 1629-1634.	2.5	43
101	SPATIOTEMPORAL DYNAMICS OF ROTAVIRUS DISEASE IN EUROPE. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 566-568.	1.1	12
102	ACUTE LIVER FAILURE ASSOCIATED WITH RUBELLA VIRUS IN A CHILD. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 573-574.	1.1	10
103	Criteria for choosing hepatitis A vaccine. <i>Practice Nursing</i> , 2010, 21, 479-482.	0.1	0
104	Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. <i>Vaccine</i> , 2010, 28, 4798-4801.	1.7	25
105	Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. <i>Vaccine</i> , 2010, 28, 5993-5997.	1.7	21
106	Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children. <i>Vaccine</i> , 2011, 29, 4735-4738.	1.7	8
107	Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1–16 years. <i>Vaccine</i> , 2011, 29, 8855-8862.	1.7	10
108	Health Advice for International Travel. , 2011, , 887-901.		0
111	Postexposure vaccines for hepatitis A. <i>The Cochrane Library</i> , 0, , .	1.5	0
116	Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: Long-term follow-up at 15 years. <i>Journal of Medical Virology</i> , 2011, 83, 1885-1891.	2.5	41
117	Long-term Durability of Immune Responses After Hepatitis A Vaccination Among HIV-Infected Adults. <i>Journal of Infectious Diseases</i> , 2011, 203, 1815-1823.	1.9	57
118	Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. <i>Hum Vaccin</i> , 2011, 7, 958-965.	2.4	34

#	ARTICLE	IF	CITATIONS
119	Hepatitis A , 2012 , , 531-539.		2
120	Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A Virus. PLoS Computational Biology, 2012, 8, e1002418.	1.5	66
121	Dominance of the CD4+ T helper cell response during acute resolving hepatitis A virus infection. Journal of Experimental Medicine, 2012, 209, 1481-1492.	4.2	79
123	New challenges in viral hepatitis. Gut, 2012, 61, i1-i5.	6.1	24
124	Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina. Hepatic Medicine: Evidence and Research, 2012, 4, 53.	0.9	18
125	Hepatitis A immunisation in persons not previously exposed to hepatitis A. The Cochrane Library, 2012, , CD009051.	1.5	22
126	Determinants of anti-hepatitis A antibody seroprevalence in 2- to 19-year-olds in the USA using NHANES 2007-2008. Epidemiology and Infection, 2012, 140, 417-425.	1.0	5
127	Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine, 2012, 31, 3-11.	1.7	74
128	Aggregate travel vs. single trip assessment: Arguments for cumulative risk analysis. Vaccine, 2012, 30, 2600-2604.	1.7	38
129	Viral hepatitis: Global goals for vaccination. Journal of Clinical Virology, 2012, 55, 296-302.	1.6	76
130	Contributions from the systematic review of economic evaluations: the case of childhood hepatitis A vaccination in Brazil. Cadernos De Saude Publica, 2012, 28, 211-228.	0.4	8
131	Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology, 2012, 56, 516-522.	3.6	29
132	Optimal approach to immunization in pediatric solid organ transplantation. Pediatric Transplantation, 2012, 16, 680-683.	0.5	4
133	Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine. Journal of Medical Virology, 2012, 84, 11-17.	2.5	18
134	Acute Viral Hepatitis in the United States-Mexico Border Region: Data from the Border Infectious Disease Surveillance (BIDS) Project, 2000-2009. Journal of Immigrant and Minority Health, 2013, 15, 390-397.	0.8	8
135	Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations. International Journal of Infectious Diseases, 2013, 17, e939-e944.	1.5	60
136	Paediatric travel medicine: vaccines and medications. British Journal of Clinical Pharmacology, 2013, 75, 1422-1432.	1.1	6
137	Hepatitis A vaccines. , 2013 , , 183-204.		9

#	ARTICLE	IF	CITATIONS
138	Consulta del niño que viaja. EMC Pediatría, 2013, 48, 1-14.	0.0	0
140	Antibody-Secreting Cells with a Phenotype of Ki-67 <sup>low</sup> , CD138 <sup>high</sup> , CD31 <sup>high</sup> , and CD38 <sup>high</sup> Secrete Nonspecific IgM during Primary Hepatitis A Virus Infection. Journal of Immunology, 2013, 191, 127-134.	0.4	16
142	Hepatitis A and hepatitis E virus infection. , 0, , 265-275.		4
143	Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial. Human Vaccines and Immunotherapeutics, 2014, 10, 3435-3445.	1.4	100
144	Effectiveness of 10-year vaccination (2001-2010) for Hepatitis A in Tianjin, China. Human Vaccines and Immunotherapeutics, 2014, 10, 1008-1012.	1.4	11
145	Long Antibody Persistence and Transgenerational Transfer of Immunity in a Long-Lived Vertebrate. American Naturalist, 2014, 184, 764-776.	1.0	22
146	Vacunación frente a la hepatitis A. Vacunas, 2014, 15, 51-58.	1.1	2
147	Live attenuated hepatitis A vaccines developed in China. Human Vaccines and Immunotherapeutics, 2014, 10, 659-666.	1.4	25
148	Field effectiveness of hepatitis A vaccine and uptake of post exposure prophylaxis following a change to the Australian guidelines. Vaccine, 2014, 32, 5509-5513.	1.7	12
149	Consultation de l'enfant voyageur. Journal De Pédiatrie Et De Puericulture, 2014, 27, 183-209.	0.0	0
150	Prioritising immunisations for travel: International and Japanese perspectives. Travel Medicine and Infectious Disease, 2014, 12, 118-128.	1.5	1
151	Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine, 2014, 32, 1507-1513.	1.7	62
152	Immunisations in Crohn's disease: Who? Why? What? When?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 485-496.	1.0	7
154	Update on foodborne viruses: types, concentration and sampling methods. , 2015, , 102-116.		3
155	Trends in Disease and Complications of Hepatitis A Virus Infection in the United States, 1999-2011: A New Concern for Adults. Journal of Infectious Diseases, 2015, 212, 176-182.	1.9	75
156	Single-Dose Universal Hepatitis A Immunization in Argentina: Low Viral Circulation and High Persistence of Protective Antibodies Up to 4 Years. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e62-e67.	0.6	19
157	Long-term Antibody Persistence in Children After Vaccination With the Pediatric Formulation of an Aluminum-free Virosomal Hepatitis A Vaccine. Pediatric Infectious Disease Journal, 2015, 34, e85-e91.	1.1	13
158	Comparison of Immunogenicity Between Inactivated and Live Attenuated Hepatitis A Vaccines Among Young Adults: A 3-Year Follow-up Study. Journal of Infectious Diseases, 2015, 212, 1232-1236.	1.9	9



#	ARTICLE	IF	CITATIONS
159	Thermal Inactivation of Foodborne Enteric Viruses and Their Viral Surrogates in Foods. <i>Journal of Food Protection</i> , 2015, 78, 1597-1617.	0.8	51
160	Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12–15 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e220-e228.	1.1	11
161	Insulin resistance increases loss of antibody to hepatitis B surface antigen in nondiabetic healthy adults. <i>Journal of Viral Hepatitis</i> , 2016, 23, 889-896.	1.0	5
162	Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw605.	1.9	21
163	Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2322-2326.	1.4	14
164	The impact of assumptions regarding vaccine-induced immunity on the public health and cost-effectiveness of hepatitis A vaccination: Is one dose sufficient?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2765-2771.	1.4	14
165	Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up. <i>Hepatology</i> , 2016, 63, 703-711.	3.6	12
166	Persistence of antibody to Hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska. <i>Journal of Viral Hepatitis</i> , 2017, 24, 608-612.	1.0	16
167	Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study. <i>Vaccine</i> , 2017, 35, 1448-1454.	1.7	26
168	Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2707-2712.	1.4	15
169	<i>Pediatric Vaccines and Vaccinations.</i> , 2017, , .		1
170	Changing Epidemiology of Hepatitis A and Hepatitis E Viruses in China, 1990–2014. <i>Emerging Infectious Diseases</i> , 2017, 23, 276-279.	2.0	30
171	<i>Hepatitis A Virus.</i> , 2018, , 1214-1219.e2.		0
173	<i>Hepatitis A Vaccines.</i> , 2018, , 319-341.e15.		8
174	Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses. <i>Frontiers in Immunology</i> , 2019, 10, 956.	2.2	90
175	Clinical experience with the inactivated hepatitis A vaccine, Avaxim 80U Pediatric. <i>Expert Review of Vaccines</i> , 2019, 18, 209-223.	2.0	9
176	Hepatitis A immunisation in persons not previously exposed to hepatitis A. <i>The Cochrane Library</i> , 0, , .	1.5	0
177	Adherence to hepatitis A travel health guidelines: A cross-sectional seroprevalence study in Dutch travelling families - The Dutch travel Vaccination Study (DiVeST). <i>Travel Medicine and Infectious Disease</i> , 2019, 32, 101511.	1.5	3

#	ARTICLE	IF	CITATIONS
178	Hepatitis A immunisation in persons not previously exposed to hepatitis A. The Cochrane Library, 2019, 12, CD009051.	1.5	3
179	Routine Travel Vaccines. , 2019, , 89-100.		1
180	Changing epidemiological characteristics of Hepatitis A and waning of Anti-HAV immunity in Beijing, China: a comparison of prevalence from 1990 to 2017. Human Vaccines and Immunotherapeutics, 2019, 15, 420-425.	1.4	15
181	Immunization against Hepatitis A. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a031682.	2.9	14
182	Hepatitis A. , 2020, , 107-112.		0
183	Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction. Human Vaccines and Immunotherapeutics, 2020, 16, 2559-2564.	1.4	6
184	Epidemiologic trends of hepatitis A in different age groups and regions of China from 1990 to 2018: observational population-based study. Epidemiology and Infection, 2021, 149, .	1.0	2
185	Hepatitis A Vaccines. , 2021, , 115-125.		0
186	Hepatitis A Infections in Transplant. , 2021, , 877-907.		0
187	Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. Vaccine, 2021, 39, 871-875.	1.7	5
188	Hepatitis A and Hepatitis E Virus in Children. , 2021, , 273-284.		0
189	Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA®, Ⓢ). Vaccine, 2021, 39, 2764-2771.	1.7	9
190	Immunogenicity of Viral Vaccines in the Italian Military. Biomedicines, 2021, 9, 87.	1.4	5
191	One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review. Vaccine, 2022, 40, 196-205.	1.7	15
192	Neonatal and Paediatric Infection. , 0, , 714-739.		2
194	Universal Mass Vaccination Against Hepatitis A. , 2006, 304, 95-114.		30
195	Hepatitis A Virus. , 2014, , 417-438.		3
196	Hepatitis A Vaccines. , 2017, , 99-108.		3

#	ARTICLE	IF	CITATIONS
197	Recommended Travel Vaccines: From "Travel Vaccine" to Universal Vaccination " The Hepatitis A Story. , 2007, , 47-57.		1
198	Hepatitis A vaccines. , 2008, , 177-203.		9
199	Hepatitis A vaccination and its immunological and epidemiological long-term effects " a review of the evidence. Human Vaccines and Immunotherapeutics, 2021, 17, 1496-1519.	1.4	29
200	LONG-TERM IMMUNITY AFTER TWO DOSES OF INACTIVATED HEPATITIS A VACCINE, IN ARGENTINEAN CHILDREN. Pediatric Infectious Disease Journal, 2010, 29, 568-570.	1.1	22
201	Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recommendations and Reports, 2020, 69, 1-38.	26.7	114
202	Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2007, 21, 345-56.	0.6	29
203	Universal vaccination of children against hepatitis a in Chile: a cost-effectiveness study. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2008, 23, 303-12.	0.6	26
204	Changing Epidemiology of Hepatitis A and Hepatitis E Viruses in China, 1990"2014. Emerging Infectious Diseases, 2017, 23, 276-279.	2.0	27
205	An epidemiologic study on the seropositive rate of hepatitis A virus among a selected group of children and adults in Busan. Korean Journal of Pediatrics, 2007, 50, 262.	1.9	11
206	Prevention of Viral Hepatitis and Vaccination. Korean Journal of Medicine, 2012, 82, 123.	0.1	4
207	Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intestinal Research, 2020, 18, 18-33.	1.0	19
208	Nationwide Hospital-Based Seroprevalence of Hepatitis A and Hepatitis E Virus in Bangladesh. Annals of Global Health, 2020, 86, 29.	0.8	9
210	Hepatitis A Virus. , 2008, , 1157-1162.		0
211	INFECTIOUS HEPATITIS. , 2009, , 527-547.		0
212	HEPATITIS A VIRUS. , 2009, , 2194-2213.		1
213	9 Virale hepatitis. , 2009, , 83-99.		0
214	ACTIVE IMMUNIZING AGENTS. , 2009, , 3340-3400.		2
215	Viral Hepatitis Vaccines. , 2011, , 671-679.		0

#	ARTICLE	IF	CITATIONS
216	Hepatitis A Virus. , 2012, , 1180-1185.e3.		0
217	Routine Travel Vaccines. , 2013, , 87-100.		0
220	Health Advice for International Travel. , 1992, , 1400-1424.		3
222	Viral Hepatitis A in Children: Detection and Management. , 2019, , 71-89.		1
224	ERKRANKUNGEN DER VERDAUUNGSORGANE. , 2020, , pA-1-pA7.8-14.		0
225	Hepatitis A Infections in Transplant. , 2020, , 1-32.		0
226	Impfungen bei gastrointestinalen Infektionen. , 2006, , 433-441.		0
227	Vaccination against hepatitis A in children: A review of the evidence. Therapeutics and Clinical Risk Management, 2007, 3, 1071-6.	0.9	10
228	Viral Hepatitis in Patients with Inflammatory Bowel Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2022, 80, 51-59.	0.2	0
229	Hepatitis A Virus. , 2023, , 1237-1243.e3.		0
230	Changing molecular epidemiology of Hepatitis A virus in Santiago, Chile from 2010 to 2021. Infection, Genetics and Evolution, 2023, 111, 105428.	1.0	0
232	Hepatitis A Virus. , 2023, , 1-47.		0